Data protection Impressum

Life sciences

On 23 and 24 September 2026, ILMAC will take place at Beaulieu Lausanne, positioning the Greater Geneva region at the centre of Switzerland's chemistry and life sciences industry under the banner "Inspiring the Future of Chemistry and Life Sciences."

ILMAC returns in September 2026 to bring together the chemistry and life sciences sector

1 June 2026

Geneva-based MindMaze Therapeutics announced a CHF 8 million strategic equity financing from Neuro.io Group, funding the expansion of its U.S. commercial operations and opening the door to a potential combination of neurotherapeutics and artificial intelligence.

MindMaze secures CHF 8 million to expand its neurotherapeutics platform

1 June 2026

CSEM and MOMM Diagnostics have developed a point-of-care preeclampsia test up to 100 times more sensitive than conventional lateral flow assays.

CSEM and MOMM Diagnostics develop rapid preeclampsia test

26 May 2026

Geneva's Neurosoft Bioelectronics has raised USD 7.5 million in an oversubscribed seed round to advance its brain interface platform and build a cortical AI model.

Neurosoft Bioelectronics raises USD 7.5 million to advance its brain interface platform

26 May 2026

The Swiss Biotech Report 2026 reveals record sector revenues and a landmark year for private funding, as talent and international collaboration continue to underpin Switzerland's position at the forefront of global life sciences.

Swiss Biotech Report 2026: talent and tenacity drive record performance

5 May 2026

Lausanne's CHUV has become the first hospital in Western Switzerland to deploy the Da Vinci Single Port robotic surgical assistant, performing minimally invasive procedures through a single 2.7 cm incision or a natural orifice across six surgical specialties.

CHUV deploys Western Switzerland’s first single-port robotic surgical assistant

29 April 2026

The applied research partnership between CSEM, the Insel Gruppe, and the University of Bern has been extended for three years, building on 32 medtech projects launched since 2023 and reinforcing Bern's ambition to become a leading international medical hub by 2030.

CSEM, Insel Gruppe, and University of Bern extend Bern medtech collaboration for three more years

20 April 2026

ONWARD Medical has secured EUR 40.6 million through an accelerated bookbuild offering led by a EUR 25 million investment from EQT Life Sciences, extending the company's cash runway into the first quarter of 2028.

ONWARD Medical raises EUR 40 million to extend ARC therapy commercialization

20 April 2026

Lausanne-based AC Immune has amended its license and collaboration agreement with Eli Lilly to advance new Tau Morphomer small molecule candidates for Alzheimer's disease and other neurodegenerative diseases, with IND-enabling studies set to commence in the first half of 2026.

AC Immune secures CHF 10 million from Lilly to advance Alzheimer’s therapy

15 April 2026

Geneva-based dEEGtal has appointed neurotechnology entrepreneur and investor Ann Bunnenberg to its board of directors, as the AI-powered brain signal platform advances clinical studies across Switzerland, Spain, and the United States ahead of a CHF 4–5 million seed round.

dEEGtal strengthens governance and advances clinical validation across three continents

14 April 2026

1 2 3 4 5 6 7 … 29